43 patents
Page 2 of 3
Utility
Method for Treatment of at Risk Patients
4 Aug 22
The invention provides an anti-fibrotic or anti-nonalcoholic steatohepatitis (NASH) drug for use in a method for reducing the risk for a subject to develop liver fibrosis or NASH, wherein the drug is administered to a subject classified as at risk to develop liver fibrosis or NASH.
JOHN BROZEK, NOÉMIE DAM, YACINE HAJJI, RÉMY HANF
Filed: 8 Jun 20
Utility
Methods of treatment for cholestatic and fibrotic diseases
2 Aug 22
The present invention relates to a synergistic combination of active ingredients for use in the treatment of fibrotic diseases.
Robert Walczak, Corinne Foucart, Philippe Delataille
Filed: 13 May 20
Utility
Nitazoxanide and Thiazolides for Use In the Treatment of Diseases Associated with Oxidative Stress
23 Jun 22
The present invention relates to novel uses of nitazoxanide, or analogues thereof.
Nicolas STANKOVIC-VALENTIN, Corinne FOUCART, Peggy PARROCHE, Robert WALCZAK
Filed: 9 Apr 20
Utility
Compositions and Methods for the Stabilization of Micro-rna
16 Jun 22
The present invention relates to the stabilization of micro-RNA molecules.
ZOUHER MAJD
Filed: 16 Apr 20
Utility
Combination of Nitazoxanide and Elafibranor for the Treatment of Immune Diseases or Inflammation
9 Jun 22
The present invention relates to a combination product comprising (i) nitazoxanide (NTZ) or an analogue thereof, and (ii) a PPAR agonist, for use in the treatment of an immune diseases or inflammation.
Peggy PARROCHE, Robert WALCZAK
Filed: 7 Apr 20
Utility
Diagnosis of Non-alcoholic Steatohepatitis
26 May 22
The present invention relates to a non-invasive method for classifying a subject as a potential receiver or non-receiver of a treatment for non-alcoholic steatohepatitis.
JOHN BROZEK
Filed: 12 Mar 20
Utility
Methods of treatment of cholestatic diseases
17 May 22
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 5 Jun 20
Utility
Methods of Treatment of Cholestatic Diseases
5 May 22
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Remy Hanf
Filed: 23 Nov 21
Utility
Rorgamma Modulators and Uses Thereof
5 May 22
The present invention provides novel compounds that are modulators of RORgamma.
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 5 Oct 21
Utility
In Vitro Model of Liver Steatosis and Fibrosing Non-alcoholic Steatohepatitis
24 Feb 22
The present invention relates to compositions and methods for preparing in vitro models of non-alcoholic fatty liver disease, and more particularly of liver steatosis and fibrosing non-alcoholic steatohepatitis (NASH).
GUILLAUME VIDAL, FLORIANE LIMOGE, JULIETTE DROUARD, ROBERT WALCZAK, CAROLE BELANGER
Filed: 18 Dec 19
Utility
Pharmaceutical compositions for combination therapy
7 Dec 21
The present invention relates to a combination product and its use in therapy.
Dean Hum, Robert Walczak, Carole Belanger, Corinne Foucart
Filed: 13 Mar 18
Utility
Methods of treatment of cholestatic diseases
30 Nov 21
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Rémy Hanf
Filed: 30 Mar 17
Utility
RORgamma modulators and uses thereof
2 Nov 21
The present invention provides novel compounds that are modulators of RORgamma.
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 29 Jan 18
Utility
Elafibranor Salts
7 Oct 21
The present invention relates to salts of elafibranor.
Karine BERTRAND, Alice ROUDOT, Marie-Jeanne JOISSAINS
Filed: 2 Aug 19
Utility
Pharmaceutical Compositions for Combination Therapy
9 Sep 21
The present invention relates to a combination product and its use in therapy.
Corinne FOUCART, Robert WALCZAK, Carole BELANGER, Benoît NOEL
Filed: 10 May 21
Utility
Methods of treatment for cholestatic and fibrotic diseases
31 Aug 21
The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
Filed: 24 Jun 20
Utility
Rorgamma modulators and uses thereof
3 Aug 21
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak, Pascal Bonnet, Jade Fogha
Filed: 29 Jan 18
Utility
N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases
6 Jul 21
The present invention provides e.g.
Jean-Francois Delhomel, Enrico Perspicace, Zouher Majd, Peggy Parroche, Robert Walczak
Filed: 29 Jan 18
Utility
Automated Pattern Recognition and Scoring Method of Histological Images
24 Jun 21
The present invention relates to a novel automated pattern recognition and scoring method of histological images.
John Brozek, Nathalie Degallaix, Benoit Noel, Elton Rexhapaj
Filed: 19 Oct 18
Utility
Pharmaceutical compositions for combination therapy
15 Jun 21
The present invention relates to a combination product and its use in therapy.
Corinne Foucart, Robert Walczak, Carole Belanger, Benoït Noel
Filed: 29 Jan 18